Article
Allergy
Charles Pilette, Giorgio Walter Canonica, Rekha Chaudhuri, Geoffrey Chupp, F. Eun-Hyung Lee, Jason Kihyuk Lee, Carlos Almonacid, Tobias Welte, Rafael Alfonso-Cristancho, Rupert W. Jakes, Aoife Maxwell, Robert G. Price, Peter Howarth
Summary: This 1-year analysis demonstrates that real-world mepolizumab treatment is clinically effective in patients with severe asthma, providing disease control while reducing the need for mOCS and SCS bursts.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Article
Critical Care Medicine
Vidushi Sood, Linda Rogers, Sandhya Khurana
Summary: Oral corticosteroid (OCS) use in severe asthma is still common despite advances in treatment, but monoclonal antibodies have been developed to reduce OCS-treated exacerbations. Strategies for managing endocrine complications associated with OCS use include identifying OCS-dependent patients, optimizing OCS dose, tapering OCS based on asthma control criteria, assessing adrenal axis integrity, and managing corticosteroid-related comorbidities.
Article
Critical Care Medicine
Lawrence D. Sher, Michael E. Wechsler, Klaus F. Rabe, Jorge F. Maspero, Nadia Daizadeh, Xuezhou Mao, Benjamin Ortiz, Leda P. Mannent, Elizabeth Laws, Marcella Ruddy, Nami Pandit-Abid, Juby A. Jacob-Nara, Rebecca Gall, Paul J. Rowe, Yamo Deniz, David J. Lederer, Megan Hardin
Summary: This study found that in patients with severe OCS-dependent asthma, dupilumab treatment can maintain long-term reduction in OCS usage and demonstrate improvements in lung function and asthma control.
Article
Immunology
Jose M. Rodrigo-Munoz, Marta Gil-Martinez, Clara Lorente-Sorolla, Raquel Garcia-Latorre, Marcela Valverde-Monge, Santiago Quirce, Joaquin Sastre, Victoria del Pozo
Summary: MicroRNA miR-144-3p is identified as a potential diagnostic biomarker for severe asthma, as its expression is associated with the severity of the disease and corticosteroid treatment. It is increased in asthmatic lungs and serum, correlating with blood eosinophilia and genes involved in asthma pathophysiology. This miRNA shows promise as a novel biomarker for severe asthma previously treated with higher doses of corticosteroids.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Allergy
Charles Pilette, Giorgio Walter Canonica, Rekha Chaudhuri, Geoffrey Chupp, F. Eun-Hyung Lee, Jason Kihyuk Lee, Carlos Almonacid, Tobias Welte, Rafael Alfonso-Cristancho, Rupert W. Jakes, Aoife Maxwell, Robert G. Price, Peter Howarth
Summary: The study demonstrates that mepolizumab treatment in patients with severe asthma can effectively reduce oral corticosteroid dosage and decrease the rate of clinically significant exacerbations.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Article
Allergy
Christian Domingo, Jorge F. Maspero, Mario Castro, Nicola A. Hanania, Linda B. Ford, David M. G. Halpin, David J. Jackson, Nadia Daizadeh, Michel Djandji, Colin P. Mitchell, Nora Crikelair, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, Benjamin Ortiz
Summary: The study analyzed the efficacy of Dupilumab in patients with OCS-dependent severe asthma, showing that Dupilumab can significantly reduce OCS dose, improve the likelihood of no longer needing OCS, reduce exacerbations, and improve lung function.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Review
Allergy
Yan Xie, Peter W. Abel, Thomas B. Casale, Yaping Tu
Summary: Asthma can be classified into T2 and non-T2 types, with non-T2 asthma being more severe and often unresponsive to treatment. Recent studies suggest that non-T2 asthma is associated with T(H)17 cell immune responses, which may contribute to corticosteroid insensitivity in asthma.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
M. Gurnell, L. G. Heaney, D. Price, A. Menzies-Gow
Summary: Secondary adrenal insufficiency often results from excessive exogenous corticosteroid therapy, particularly oral corticosteroids. Biologic therapies offer a potential solution for reducing or eliminating maintenance OCS in severe asthma, but there is a need for further clinical trials to define strategies for early identification and treatment of AI, as well as safe OCS withdrawal in routine practice.
JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Respiratory System
Alberta L. Wang, Lies Lahousse, Amber Dahlin, Ahmed Edris, Michael McGeachie, Sharon M. Lutz, Joanne E. Sordillo, Guy Brusselle, Jessica Lasky-Su, Scott T. Weiss, Carlos Iribarren, Meng X. Lu, Kelan G. Tantisira, Ann C. Wu
Summary: This study identified multiple novel SNPs associated with ICS response in older adult asthmatics. Some of these SNPs were annotated to genes previously associated with asthma and other airway or allergic diseases, such as PTCHD4.
Article
Pharmacology & Pharmacy
Christian Domingo, Rosa M. Mirapeix, Francisco-Javier Gonzalez-Barcala, Carles Forne, Felip Garcia
Summary: This study aimed to demonstrate that omalizumab is a corticosteroid-sparing therapy in patients with corticosteroid-dependent asthma, able to inhibit airway remodeling and reduce disease burden. The results showed that omalizumab significantly reduced the use of corticosteroids, improved lung function, reduced exacerbations, and facilitated bronchial epithelial repair.
Article
Allergy
Akihiko Tanaka, Mai Takahashi, Ayako Fukui, Yoshifumi Arita, Masakazu Fujiwara, Naoyuki Makita, Naoki Tashiro
Summary: This study compared the reduction in oral corticosteroid (OCS) dose between severe asthma patients initiated with biologics (BIOs) and those not initiated with BIOs. The results showed a significant reduction in maintenance OCS dose in patients treated with BIOs compared to those not treated with BIOs. However, there was no clear difference in the extent of OCS dose reduction between the two groups.
JOURNAL OF ASTHMA AND ALLERGY
(2023)
Article
Allergy
Carlos Cardoso-Vigueros, Tobias von Blumenthal, Beate Rueckert, Arturo O. Rinaldi, Ge Tan, Anita Dreher, Urszula Radzikowska, Gunter Menz, Peter Schmid-Grendelmeier, Cezmi A. Akdis, Milena Sokolowska
Summary: This study aimed to determine the utility of leukocyte redistribution as a biomarker of disease heterogeneity in patients with severe asthma and as a bioindicator of potential corticosteroid resistance. Through clinical data analysis and flow cytometry, we identified two clusters of severe asthma patients with differences in cell frequencies, response to corticosteroids, and atopy status.
CLINICAL AND EXPERIMENTAL ALLERGY
(2022)
Article
Respiratory System
Heath Heatley, Trung N. Tran, Arnaud Bourdin, Andrew Menzies-Gow, David Joshua Jackson, Ekaterina Maslova, Jatin Chapaneri, Derek Skinner, Victoria Carter, Jeffrey Shi Kai Chan, Con Ariti, John Haughney, David B. Price
Summary: Intermittent oral corticosteroid (OCS) use for asthma is associated with increased risks of adverse outcomes. More frequent prescribing patterns of OCS are associated with higher risks of adverse outcomes, particularly pneumonia and sleep apnea. Mitigation strategies are needed to minimize intermittent OCS prescription in primary care.
Article
Allergy
Fahad H. Alahmadi, Brian Keevil, Lynn Elsey, Kate George, Robert Niven, Stephen J. Fowler
Summary: LC-MS/MS can reliably detect commonly used ICSs in the blood at least 8 hours after dosing, providing a measure of adherence in severe asthma patients. Lower blood levels were associated with higher exacerbation rates and poorer lung function.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Critical Care Medicine
Alexandra M. Nanzer, Adam Lawton, Grainne D'Ancona, Atul Gupta
Summary: Adolescent asthma patients require special attention and care, facing challenges in disease management and the need for transition during their adolescence.
Article
Public, Environmental & Occupational Health
Hannes Wartmann, Sarah Hoffmann, Tobias Ruck, Christopher Nelke, Barthold Deiters, Timm Volmer
Summary: This is a study on the prevalence and incidence rates of myasthenia gravis (MG) in Germany. The study found that the prevalence rate of MG increased by 1.8-fold over the past 10 years, while the incidence rate decreased significantly in 2020 due to the impact of the COVID-19 pandemic. Treatment patterns are also changing, with an increasing use of therapeutic monoclonal antibodies.